- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01994733
Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET) (TARGET)
June 22, 2015 updated by: Ron Wald, Unity Health Toronto
Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET): Intensive vs Liberalized Phosphate Control in Hemodialysis Recipients
Patients with end-stage renal disease (ESRD) who have elevated serum phosphate (P) levels have significantly higher mortality rates compared to those with normal P. In patients receiving conventional dialysis regimens, serum P may be lowered through dietary intervention and use of P binders, though these have potentially important side effects and may adversely impact quality of life.
Whether lowering P, and / or targeting specific P levels improve survival and clinical outcomes is unknown.
Despite this uncertainty, over 90% of patients with ESRD receive P lowering therapy and guidelines for the care of patients with ESRD are increasingly calling for more aggressive phosphate lowering.
This intensive P lowering results in extra medications (and their associated side-effects), and higher health care costs.
We are uncertain whether the intensification of P control results in measurable benefits to patients with ESRD.
The overall goal of this pilot trial is to evaluate the feasibility of conducting a randomized controlled trial of intensive vs liberalized phosphate control among hemodialysis recipients.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Medical Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Capital District Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare
-
London, Ontario, Canada, N6G 2V4
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 yrs
- Receiving chronic hemodialysis for > 90 days,
- Dialysis prescription is currently no more than 4 sessions per week and prescribed as 3-5 hrs per session
- Most recent P value 1.30-2.50 mmol/L
- Receipt of a calcium-based P binder
Exclusion Criteria:
- Patient is booked (with a known surgical date) for a live donor kidney transplant in the next 26 weeks
- Planned switch to a dialysis schedule that involves > 16 hours per week of therapy within the next 26 weeks.
- Planned switch to peritoneal dialysis within the next 26 weeks
- Pregnancy
- Albumin-corrected serum calcium > 2.60 mmol/L in the past year requiring reduction of the calcium carbonate dose
- History of calciphylaxis
- Attending nephrologist believes that an otherwise eligible patient is mandated- on clinical grounds- to have a P value that is targeted to < 1.50 mmol/L or > 2.00 mmol/L
- Attending nephrologist believes an otherwise eligible patient is not a candidate for escalation of the current calcium dose
- Co-enrollment in a clinical trial where the intervention is deemed to interfere with the adherence, safety or efficacy of the intervention provided herein
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive phosphate control
Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines.
Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction.
Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
|
Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines.
Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction.
Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
Other Names:
|
Active Comparator: Liberalized phosphate control
Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L.
This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below).
"Rescue" P binding will be instituted if P rises above 2.50 mmol/L.
Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L.
|
Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L.
This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below).
"Rescue" P binding will be instituted if P rises above 2.50 mmol/L.
Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum phosphate concentration
Time Frame: 26 weeks
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients who successfully achieved target serum P at week 26 based on the arm to which they were randomized
Time Frame: 26 weeks
|
26 weeks
|
Treatment compliance as defined by taking the study medication at least 80% of the time
Time Frame: 26 weeks
|
26 weeks
|
Number of serious adverse events
Time Frame: 26 weeks
|
26 weeks
|
Number of hospitalizations for vascular reasons that are unrelated to dialysis access
Time Frame: 26 weeks
|
26 weeks
|
Proportion of patients with a vascular death or non-fatal vascular event
Time Frame: 26 weeks
|
26 weeks
|
Proportion of patients developing serum calcium > 2.60 mmol/L
Time Frame: 26 weeks
|
26 weeks
|
Number of fractures
Time Frame: 26 weeks
|
26 weeks
|
Number of patients developing calcific uremic arteriolopathy (ie, calciphylaxis)
Time Frame: 26 weeks
|
26 weeks
|
Change in quality-of-life
Time Frame: 26 weeks
|
26 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ron Wald, MDCM, Unity Health Toronto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
November 20, 2013
First Submitted That Met QC Criteria
November 25, 2013
First Posted (Estimate)
November 26, 2013
Study Record Updates
Last Update Posted (Estimate)
June 23, 2015
Last Update Submitted That Met QC Criteria
June 22, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Kidney Diseases
- Kidney Failure, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Calcium
- Calcium, Dietary
- Calcium Carbonate
Other Study ID Numbers
- 001 (NavyGHB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Calcium carbonate ( Intensive phosphate control)
-
Creighton UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompleted
-
The University of QueenslandNational Health and Medical Research Council, Australia; Cambridge University... and other collaboratorsRecruitingKidney Failure, Chronic | HyperphosphatemiaCanada, United Kingdom, Australia, Brazil, New Zealand
-
ArdelyxCompletedHyperphosphatemiaUnited States
-
Chugai Pharma TaiwanCompletedHemodialysis | Hyperphosphatemia | Cardiovascular Events
-
BayerRecruitingHealthy Volunteers | Heartburn | Indigestion | Stomach Acid Related Symptoms | Nocturnal Stomach Acid Related SymptomsUnited Kingdom
-
Karolinska University HospitalCompleted
-
Harvard School of Public Health (HSPH)Ifakara Health Institute; St. John's Research Institute; Africa Academy for Public...CompletedPregnancy RelatedTanzania, India
-
China Medical University HospitalRecruitingRheumatoid Arthritis | Osteopenia or OsteoporosisTaiwan
-
BayerCompleted